Temasek's India journey represents a remarkable transformation from a $10 billion exposure a decade ago to approximately $50 billion today, with India now accounting for 8% of its global portfolio—nearly double the share from five years ago. This growth has been accompanied by a strategic evolution beyond traditional strongholds in consumer, healthcare, and financial services into industrials, infrastructure, and space-tech.
The shift reflects both deliberate strategy and opportunistic execution. While core sectors remain fundamental, Temasek is actively exploring emerging areas like artificial intelligence and space technology, recognizing India's potential as a leader in satellite communications given its low-cost launch capabilities. The firm's ability to deploy $3 billion annually in India stems from exceptional performance—India has been Temasek's best-performing market globally over the past decade—combined with a maturing market that now supports larger, more concentrated investments.
Temasek's preference for follow-on investments in companies like CureFit Healthcare, Manipal Health, and Licious reflects a sophisticated risk-adjusted approach. Rather than spreading capital across numerous early-stage bets, Temasek concentrates resources on proven performers, leveraging existing relationships and deep due diligence to enhance returns while managing risk. This strategy is exemplified by its $1 billion investment in Haldiram's for a 10% stake and the $2 billion additional investment in Manipal Hospitals to reach 59% ownership.
The firm's increasing openness to control deals aligns with its global structure, where nearly 40% of portfolio companies are majority-owned. In India, this is evident in the Manipal Hospitals acquisition and the aggressive platform-building strategy that followed, including the ₹5,900 crore acquisition of Sahyadri Hospitals to create India's largest private hospital chain with 49 hospitals and 12,000 beds.
Temasek's direct investments are strategically complemented by fund investments through vehicles like NIIF (up to $400 million commitment), InfoEdge Ventures ($162.5 million across three funds), and Innovation Capital. These provide access to specialized sectors, early-stage opportunities, and local expertise while maintaining diversification. The fund investments serve multiple purposes: filling gaps in Temasek's direct coverage, testing new sectors before direct investment, and building relationships with entrepreneurs early in their journey.
Temasek's exit capabilities have been demonstrated through multiple channels. The $6.4 billion sale of its 35% stake in Schneider Electric India generated over 10x returns on invested capital over seven years. The exit was driven by Schneider Electric's strategic need for full ownership to accelerate decision-making in India, its third-largest market and one of four global hubs.
Public listings have provided additional monetization opportunities. Dr. Agarwal's IPO, Lenskart's ₹7,278 crore offering, Pine Labs' ₹3,899 crore listing, and CleanMax's upcoming IPO all represent strategic exits that recycle capital for redeployment. The O2 Power exit—a $1.5 billion sale to JSW Energy—demonstrates successful platform building, with the joint venture growing from greenfield to 4.7 GW capacity in four years.
The expected $1 billion IPO of Manipal Hospitals, targeting a $10-13 billion valuation, represents a partial monetization strategy that will provide liquidity while maintaining strategic position.
Temasek's India success relative to other sovereign wealth funds stems from several advantages. Unlike GIC's diversified portfolio approach or ADIA's gradual market entry, Temasek combines first-mover advantage (investing in India for over two decades) with superior performance and operational expertise. While other SWFs like Mubadala and QIA are increasing their India presence, Temasek's established relationships, deep sector knowledge, and proven exit capabilities create sustainable competitive advantages.
In financial services, Temasek's deep expertise across ~20 companies including NSE and Axis Bank contrasts with GIC's broader but less concentrated approach. In healthcare, Temasek's operational capabilities and platform-building strategy (Manipal + Sahyadri) differentiate it from other SWFs' more passive investment styles. In renewables, Temasek's proven ability to build and exit platforms (O2 Power) demonstrates superior operational capabilities compared to funds that primarily invest through financial vehicles.
Temasek drives value creation through geographical expansion and bolt-on acquisitions. Manipal Hospitals' aggressive expansion from 29 to 49 hospitals, and Haldiram's global push into 80+ countries with new manufacturing facilities in London and QSR formats in Dubai, exemplify this strategy.
AI adoption serves as a critical enabler across the portfolio. Rather than treating AI as a standalone investment, Temasek focuses on ensuring the remaining 85% of its portfolio companies leverage AI for competitiveness. This drives revenue growth through enhanced customer experience and new product development, while improving operational efficiency through process automation and predictive analytics.
Active ownership, whether through control positions like Manipal or strategic minority stakes in Axis Bank and NSE, allows Temasek to influence strategic direction, implement global best practices, and facilitate cross-portfolio synergies. This hands-on approach, combined with permanent capital and global expertise, has enabled Temasek to create sustainable competitive advantages that are difficult for other sovereign wealth funds to replicate.
